

132/LG/SE/JUNE/2023/GBSL

June 16, 2023

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001
Scrip Code: 509079

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
Scrip Symbol: GUFICBIO

Dear Sir/Madam,

Sub.: Press Release - Gufic receives approval from NMPA, China for Prilocaine API

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith a press release being issued by the Company on the captioned subject, the contents of which is self-explanatory.

The same is submitted for public dissemination and for your record.

Thanking You,

Yours truly,

For Gufic Biosciences Limited

Ami Shah
Company Secretary & Compliance Officer
Membership No. A39579

Encl.: As above



GUFIC RECEIVES NMPA CHINA APPROVAL FOR PRILOCAINE API

Gufic Biosciences Limited (Gufic) have received approval from National Medical Products Administration (NMPA), China for our product PRILOCAINE (API) which is an amide-type local anaesthetic of fast onset and intermediate duration of action. This approval shall help commercialization of the said product in China and explore Chinese market.

About Prilocaine

Prilocaine has a clinical profile similar to lidocaine and is used for infiltration, peripheral nerve blocks and spinal and epidural anaesthesia. Also, in combination with lidocaine, it is used for surface anaesthesia.

Prilocaine offers a significantly greater duration and safety margin without a vasopressor. Hence, addition of epinephrine is not necessary to prolong the duration of action, which can be an advantage when epinephrine is contraindicated.

Prilocaine shows the least systemic toxicity of all amide local anaesthetics and is therefore useful for intravenous regional anaesthesia.

Prilocaine has the highest clearance of all amino-amide local anaesthetics, more than twice the clearance of lidocaine. Together with its larger distribution volume, this feature is responsible for the considerably lower prilocaine plasma concentration compared to lidocaine and mepivacaine after regional anaesthesia. As a consequence, prilocaine reaches toxic blood concentrations very rarely.

Prilocaine is associated with far fewer reported cases of transient neurological symptoms than lidocaine or mepivacaine.

About Gufic

Gufic is engaged in the Research and Development, manufacturing, marketing, distribution and sale of pharmaceutical and allied products. Gufic is known and respected for innovative and high quality pharmaceutical and Herbal products along with a wide range of Active Pharmaceutical Ingredients (APIs). Gufic is one of the fastest growing company among the top 100 pharma companies in India and is also one of the largest manufacturers of Lyophilized injections in India having a fully automated lyophilization plant. The lyophilized products are available in Therapeutic areas like Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and Proton-Pump Inhibitor (PPI). Gufic is now augmenting its global focus by deepening the presence in the priority markets of India, Germany, Switzerland, South Africa, Russia, Canada, Europe and other key countries within the emerging market territories. Gufic aims at providing lifesaving drugs to people at affordable prices with no compromise in its quality. Gufic is a WHO-GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA and Uganda NDA approved company with a total capacity of 48 million lyophilized vials per annum.